Table 4. Association between morphologic CT characteristics and EGFR mutation status in patients with advanced LUAD.
| CT characteristics | Driver-gene negative (n=24) | EGFR positive (n=69) | P value |
|---|---|---|---|
| Size (cm), mean ± SD | 42.92±20.67 | 37.72±17.18 | 0.268 |
| Lesion morphology, n (%) | 0.062 | ||
| Nodule (<3 cm) | 5 (20.8) | 28 (40.6) | |
| Mass (≥3 cm) | 19 (79.2) | 38 (55.1) | |
| Inflammatory type | 0 (0.0) | 3 (4.3) | |
| Location, n (%) | 0.343 | ||
| RUL | 5 (20.8) | 21 (30.4) | |
| RML | 1 (4.2) | 9 (13.0) | |
| RLL | 3 (12.5) | 12 (17.4) | |
| LUL | 10 (41.7) | 18 (26.1) | |
| LLL | 5 (20.8) | 9 (13.0) | |
| Axial location, n (%) | 0.242 | ||
| Inner | 1 (4.2) | 10 (14.5) | |
| Middle | 5 (20.8) | 18 (26.1) | |
| Peripheral | 18 (75.0) | 41 (59.4) | |
| Necrosis, n (%) | 0.681 | ||
| 0–25% | 17 (70.8) | 55 (79.7) | |
| 25–50% | 3 (12.5) | 6 (8.7) | |
| 50–75% | 2 (8.3) | 6 (8.7) | |
| 75–100% | 2 (8.3) | 2 (2.9) | |
| Pleural tag, n (%) | 9 (37.5) | 49 (71.0) | 0.004* |
| Air bronchogram, n (%) | 5 (20.8) | 25 (36.2) | 0.256 |
| Calcification, n (%) | 2 (8.3) | 10 (14.5) | 0.673 |
| Cavitation, n (%) | 1 (4.2) | 6 (8.7) | 0.783 |
| Well defined, n (%) | 19 (79.2) | 56 (81.2) | 1.000 |
| Lobulation, n (%) | 21 (87.5) | 54 (78.3) | 0.492 |
| Spiculation, n (%) | 19 (79.2) | 54 (78.3) | 0.926 |
| Vessel convergence, n (%) | 5 (20.8) | 28 (40.6) | 0.037* |
| Vascular involvement, n (%) | 7 (29.2) | 28 (40.6) | 0.320 |
| Metastasis, n (%) | |||
| Pleural | 9 (37.5) | 26 (37.7) | 0.987 |
| Lung | 9 (37.5) | 37 (53.6) | 0.174 |
| Bone | 4 (16.7) | 25 (36.2) | 0.075 |
| Liver | 0 (0.0) | 6 (8.7) | 0.312 |
| Adrenal | 0 (0.0) | 5 (7.2) | 0.406 |
| Brain | 1 (4.2) | 6 (8.7) | 0.783 |
| Pleural lesion, n (%) | 0.540 | ||
| None | 13 (54.2) | 28 (40.6) | |
| Effusion | 2 (8.3) | 13 (18.8) | |
| Metastasis | 3 (12.5) | 9 (13.0) | |
| Both effusion and metastasis | 6 (25.0) | 19 (27.5) | |
| Lung metastasis type, n (%) | 0.020* | ||
| Nodular lesion | 4 (16.7) | 33 (47.8) | |
| Lymphangitic | 2 (8.3) | 2 (2.9) | |
| Both nodular and lymphangitic | 3 (12.5) | 2 (2.9) |
*, P<0.05 was considered as statistically significant. Patients negative for EGFR, KRAS, BRAF, HER2, MET, ALK, RET and ROS1 were identified as “driver-gene-negative”. CT, computed tomography; LUAD, lung adenocarcinomas; RUL, right upper lobe, RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.